norelgestromin


Also found in: Wikipedia.

norelgestromin

A progestogen drug used in conjunction with ETHINYLOESTRADIOL (ethinylestradiol) as an oral or patch contraceptive.A brand name is Evra.
References in periodicals archive ?
The effects on IGF-1, prominent with oral oestrogens, are minimal with transdermal formulations [50]; therefore, we exclude the influence of contraceptive patches (containing a combination of ethinyl oestradiol and norelgestromin) in her IGF-1 measurements.
The primary objective was the pharmacokinetics of norgestimate, as determined by measuring the levels of its main metabolite, norelgestromin. Secondary objectives included pharmacodynamics, as determined by the levels of serum progesterone and the safety/tolerability of DMF.
TABLE 3 A look at 4 generations of progestins (6) First generation Ethynodiol diacetate Norethindrone Second generation Levonorgestrel Norgestrel Third generation Desogestrel Etonogestrel * Gestodene ([dagger]) Norgestimate Norelgestromin ([double dagger]) Fourth generation Dienogest Drospirenone * Metabolite of desogestrel, contained in the vaginal ring and subdermal implant, ([dagger]) Currently not approved by the US Food and Drug Administration, but under review as a new patch.
Pharmaceutical company Mylan (NasdaqGS:MYL) revealed on Wednesday the market launch of its US Food and Drug Administration (FDA) approved XULANE (Norelgestromin / Ethinyl Estradiol Transdermal System 150/35 mcg per day).
The contraceptive Ortho Evra is a transdermal (through the skin) patch approved by the FDA in 2001 that contains ethinyl estradiol and the progesterone norelgestromin. The one-and-three-quarter-inch patch is applied to the skin (abdomen, buttocks or upper torso, but not breasts) where it slowly releases hormones for a week.
a review of combined contraceptives containing chlormadinone, desogestrel, dienogest, drospirenone, etonogestrel, gestodene, nomegestrol, norelgestromin and norgestimate
(1) Concerns exist that drospirenone-containing combined oral contraceptives (OCs), the norelgestromin patch, and the etonogestrel vaginal ring may increase the risk of VTE, compared with second-generation OCs, although results from studies evaluating the thromboembolic risk of these products are conflicting.
This is a transdermal patch that delivers 20 [micro]g EE and 150 [micro]g norelgestromin daily.
For the study, 35 healthy premenopausal women had a 2-month phase-in period on an oral contraceptive (Ortho-Cyclen; 35 meg ethinyl estradiol and 0.25 mg norgestimate) and were then randomly assigned in a three-way crossover design to 2 months on either the oral contraceptive, a patch formulation (Ortho-Evra; approximating a daily dose of 20 mcg ethinyl estradiol and 150 mcg norelgestromin), or an extended-release patch (Extended Ortho-Evra).
Each patch contains 6 mg of norelgestromin and 0.6 mg of ethinyl estradiol.
Other newer methods include the contraceptive patch that delivers 150 mcg of norelgestromin and 20 mcg of ethinyl estradiol per day and is replaced weekly for 3 weeks, followed by 1 week with no patch.
Ortho-Evra is marketed by Merck & Co and contains norelgestromin and ethinyl estradiol (EE).